X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Acyclovir is a synthetic purine nucleoside analogue having high affinity for the enzyme thymidine kinase encoded by HSV and VZV. It has shown in vitro and in vivo inhibitory activity against herpes simplex virus types 1, 2 and varicella-zoster virus (VZV).
Lead Product(s): Aciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Zovirax-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex.
Lead Product(s): Letermovir,Aciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
Apotex Inc. is recalling certain lots of Apo-Acyclovir (acyclovir) tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity (N-nitrosodimethylamine [NDMA]) above the acceptable level.
Lead Product(s): Aciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Apo-Acyclovir
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Under the new Agreement, Sol-Gel has retained collaboration rights to two generic programs acyclovir cream and ivermectin cream related to four generic drug candidates that it believes to have the most value-generating potential.
Lead Product(s): Aciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Acyclovir-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Padagis
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 04, 2021
Details:
Novitium Pharma's lead drug, Acyclovir oral suspension, is a synthetic nucleoside analogue active against herpesviruses. The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV.
Lead Product(s): Aciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ANI Pharmaceuticals Inc
Deal Size: $372.5 million Upfront Cash: $89.5 million
Deal Type: Acquisition March 09, 2021
Details:
The agreement gives SYB the right to register, manufacture and market the product in China.
Lead Product(s): Aciclovir,Hydrocortisone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shijiazhuang Yuanmai Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
